This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nayak, M. S. Articles by Hait, W. N. Search for Related Content PubMed PubMed Citation Articles by Nayak, M. S. Articles by Hait, W. N.

Effect of a Single Nucleotide Polymorphism in the Murine Double Minute 2 Promoter (SNP309) on the Sensitivity to Topoisomerase II–Targeting Drugs

Departments of Pharmacology and Medicine, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey

Requests for reprints: Jin-Ming Yang and William N. Hait, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901. Phone: 732-235-8075; Fax: 732-235-8094; E-mail: jyang{at}umdnj.edu and haitwn{at}umdnj.edu.

A single nucleotide polymorphism (SNP) SNP309 (TG) in the murine double minute 2 (MDM2) promoter creates a high-affinity Sp1 binding site and increases the expression of MDM2 mRNA and protein. Approximately 40% of the populations harbor at least one variant allele and 12% to 17% are homozygous G/G at codon 309. This MDM2 SNP increases susceptibility to cancer and decreases the response of cancer cells to certain forms of treatment, such as radiation therapy and DNA-damaging drugs. Topoisomerase II (TopoII)–targeting agents are commonly used chemotherapeutic drugs with a broad spectrum of activity. However, resistance to TopoII poisons limits their effectiveness. We show that MDM2 SNP309 rendered a panel of cancer cell lines that are homozygous for SNP309 selectively resistant (10-fold) to certain TopoII-targeting chemotherapeutic drugs (etoposide, mitoxantrone, amsacrine, and ellipticine). The mechanism underlying this observation was Mdm2-mediated down-regulation of TopoII; on drug exposure, MDM2 bound to TopoII and resulted in decreased cellular enzyme content. Knockdown of MDM2 by RNA interference stabilized TopoII and decreased resistance to TopoII-targeting drugs. Thus, MDM2 SNP309 (TG) may represent a relatively common, previously unappreciated determinant of drug sensitivity. Given the frequency of SNP309 in the general population (40% in heterozygous T/G and 12% in homozygous G/G condition), our observation may have important implications for the individualization of cancer chemotherapy. [Cancer Res 2007;67(12):5831–9]

This article has been cited by other articles:

				G. S. Atwal, T. Kirchhoff, E. E. Bond, M. Montagna, C. Menin, R. Bertorelle, M. C. Scaini, F. Bartel, A. Bohnke, C. Pempe, et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene PNAS, June 23, 2009; 106(25): 10236 - 10241. [Abstract] [Full Text] [PDF]

				H. Taubert, F. Bartel, T. Greither, M. Bache, M. Kappler, T. Kohler, A. Bohnke, C. Lautenschlager, H. Schmidt, H.-J. Holzhausen, et al. Association of HDM2 Transcript Levels with Age of Onset and Prognosis in Soft Tissue Sarcomas Mol. Cancer Res., October 1, 2008; 6(10): 1575 - 1581. [Abstract] [Full Text] [PDF]

				Z. Duan, E. J. Weinstein, D. Ji, R. Y. Ames, E. Choy, H. Mankin, and F. J. Hornicek Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer Mol. Cancer Ther., August 1, 2008; 7(8): 2377 - 2385. [Abstract] [Full Text] [PDF]

				K. Terry, M. McGrath, I-M. Lee, J. Buring, and I. De Vivo MDM2 SNP309 Is Associated with Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 983 - 986. [Abstract] [Full Text] [PDF]